12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BST-CarGel: Phase III data

An international, blinded Phase III trial in 80 patients aged 18-55 with single symptomatic grade III/IV focal lesions on femoral condyles showed that BST-CarGel met the co-primary endpoints of greater lesion filling and superior repair tissue quality at 12 months vs. standard of care...

Read the full 197 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >